Skip to main content

Treatment and Prevention of Multidrug-Resistant Tuberculosis

Drugs volume 58, pages 633–661 (1999)Cite this article

Abstract

Multidrug-resistant tuberculosis (MDRTB), which is defined as combined resistance to isoniazid and rifampicin, is a ‘man-made’ disease that is caused by improper treatment, inadequate drug supplies or poor patient supervision. Patients with MDRTB face chronic disability and death, and represent an infectious hazard for the community. Cure rates of 96% have been achieved but require prompt recognition of the disease, rapid accurate susceptibility results, and early administration of an individualised re-treatment regimen. Such regimens are usually based on a quinolone and an injectable agent (i.e. an aminoglycoside or capreomycin) supplemented by other ‘second-line’ drugs. This therapy is prolonged (e.g. 24 months), expensive, and has multiple adverse effects.

Prevention of MDRTB is therefore of paramount importance. The World Health Organization (WHO) has recommended a multifaceted programme, known by the acronym DOTS (directly observed therapy, short-course), that promotes effective treatment of drug-susceptible TB as the prime method of limiting drug resistance. DOTS was part of a successful MDRTB control programme in New York City, which also included treatment of prevalent MDRTB cases, streamlined laboratory testing, effective infection control procedures and wider application of screening and preventive therapy (although the optimal chemotherapy for MDRTB infection remains undefined).

Industrialised countries have the resources to treat patients with MDRTB and to mount these extensive control programmes. Unfortunately, MDRTB is also prevalent in Asia, South America and the former Soviet Union. First world countries have a vested interest, as well as a moral responsibility, to assist in controlling MDRTB in these ‘hot spots’.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

49,54 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

References

  1. Dolin PJ, Raviglione MC, Kochi A. Global tuberculosis incidence and mortality during 1990–2000. Bull World Health Organ 1994; 72: 213–20

    PubMed  CAS  Google Scholar 

  2. Raviglione MC, Snider DE, Kochi A. Global epidemiology of tuberculosis: morbidity and mortality of a worldwide epidemic. JAMA 1995; 273: 220–6

    PubMed  CAS  Article  Google Scholar 

  3. Murray CJL, Styblo K, Rouillon A. Tuberculosis in developing countries: burden, intervention and cost. Bull Int Union Tuberc Lung Dis 1990; 65: 6–24

    PubMed  CAS  Google Scholar 

  4. Cantwell MF, Snider DE, Cauthen GM, et al. Epidemiology of tuberculosis in the United States, 1985 through 1992. JAMA 1994; 272: 535–9

    PubMed  CAS  Article  Google Scholar 

  5. Bhatti N, Law MR, Morris JK, et al. Increasing incidence of tuberculosis in England and Wales: a study of the likely causes. BMJ 1995; 310: 967–9

    PubMed  CAS  Article  Google Scholar 

  6. Raviglione MC, Rieder HL, Styblo K, et al. Tuberculosis trends in Eastern Europe and the former USSR. Tuber Lung Dis 1994; 75: 400–16

    PubMed  CAS  Article  Google Scholar 

  7. Raviglione MC, Sudre P, Reider HL, et al. Secular trends in tuberculosis in Western Europe. Bull World Health Organ 1993; 71: 297–306

    PubMed  CAS  Google Scholar 

  8. Cohn DL, Bustreo F, Raviglione MC. Drug-resistant tuberculosis: review of the worldwide situation and the WHO/IUATLD global surveillance project. Clin Infect Dis 1997; 24 Suppl. 1: S121–30

    PubMed  Article  Google Scholar 

  9. Pablos-Mendez A, Raviglione MC, Laszlo A, et al. Global surveillance for antituberculosis-drug resistance, 1994–1997. N Engl J Med 1998; 338: 1641–9

    PubMed  CAS  Article  Google Scholar 

  10. Bloch AB, Cauthen GM, Onorato IM, et al. Nationwide survey of drug-resistant tuberculosis in the United States. JAMA 1994; 271: 665–71

    PubMed  CAS  Article  Google Scholar 

  11. Kaye K, Frieden TR. Tuberculosis control: the relevance of classic principles in an era of acquired immunodeficiency syndrome and multidrug resistance. Epidemiol Rev 1996; 18: 52–63

    PubMed  CAS  Article  Google Scholar 

  12. Brudney K, Dobkin J. Resurgent tuberculosis in New York City: human immunodeficiency virus, homelessness, and the decline of tuberculosis control programs. Am Rev Respir Dis 1991; 144: 745–9

    PubMed  CAS  Article  Google Scholar 

  13. Barr RG, Menzies R. The effect of war on tuberculosis. Tuber Lung Dis 1994; 75: 251–9

    PubMed  CAS  Article  Google Scholar 

  14. Gibson N, Boillot F, Jalloh H. The cost of tuberculosis to patients in Sierra Leone’s war zone. Int J Tuberc Lung Dis 1998; 2: 726–31

    PubMed  CAS  Google Scholar 

  15. Spence DPS, Hotchkiss J, Williams CSD, et al. Tuberculosis and poverty. BMJ 1993; 307: 759–61

    PubMed  CAS  Article  Google Scholar 

  16. Mahmoudi A, Iseman MD. Pitfalls in the care of patients with tuberculosis: common errors and their association with the acquisition of drug resistance. JAMA 1993; 270: 65–8

    PubMed  CAS  Article  Google Scholar 

  17. Liu Z, Shilkret KL, Finelli L. Initial drug regimens for the treatment of tuberculosis: evaluation of physician prescribing practices in New Jersey, 1994 to 1995. Chest 1998; 113: 1446–51

    PubMed  CAS  Article  Google Scholar 

  18. Sumartojo E. When tuberculosis treatment fails: a social behavioral account of patient adherence. Am Rev Respir Dis 1993; 147: 1311–20

    PubMed  CAS  Google Scholar 

  19. Goble M, Iseman MD, Madsen LA, et al. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med 1993; 328: 527–32

    PubMed  CAS  Article  Google Scholar 

  20. Crofton J, Chaulet P, Maher D, et al. Guidelines for the management of drug resistant tuberculosis. Geneva: World Health Organization, 1997. Publication no. WHO/TB/96.210

    Google Scholar 

  21. Iseman MD, Madsen LA. Drug-resistant tuberculosis. Clin Chest Med 1989; 10: 341–53

    PubMed  CAS  Google Scholar 

  22. Pearson ML, Jereb JA, Frieden TR, et al. Nosocomial transmission of multidrug-resistant tuberculosis: a risk to patients and health care workers. Ann Intern Med 1992; 117: 191–6

    PubMed  CAS  Google Scholar 

  23. Beck-Sague C, Dooley SW, Hutton MD, et al. Hospital outbreak of multidrug-resistant Mycobacterium. tuberculosis infections: factors in transmission to staff and HIV-infected patients. JAMA 1992; 268: 1280–6

    PubMed  CAS  Article  Google Scholar 

  24. Reeves R, Blakey D, Snider DE, et al. Transmission of multiple drug-resistant tuberculosis: report of a school and community outbreak. Am J Epidemiol 1981; 113: 423–35

    Google Scholar 

  25. Centers for Disease Control. Outbreak of multidrug-resistant tuberculosis — Texas, California and, Pennsylvania. MMWR Morb Mortal Wkly Rep 1990; 39: 369–72

    Google Scholar 

  26. Iseman MD. Treatment of multidrug-resistant tuberculosis. N Engl J Med 1993; 329: 784–91

    PubMed  CAS  Article  Google Scholar 

  27. Centers for Disease Control. Nosocomial transmission of multidrug-resistant tuberculosis among HIV-infected persons-Florida and New York, 1988–1991. MMWR Morb Mortal Wkly Rep 1991; 40: 585–91

    Google Scholar 

  28. Fischl MA, Daikos GL, Uttamchandani RB, et al. Clinical presentation and outcome of patients with HIV infection and tuberculosis caused by multiple-drug-resistant bacilli. Ann Intern Med 1992; 117: 184–90

    PubMed  CAS  Google Scholar 

  29. Frieden TR, Fujiwara PI, Washko RM, et al. Tuberculosis in New York City — turning the tide. N Engl J Med 1995; 333: 229–33

    PubMed  CAS  Article  Google Scholar 

  30. Moore M, Onorato IM, McCray E, et al. Trends in drug-resistant tuberculosis in the United States, 1993–1996. JAMA 1997; 278: 833–7

    PubMed  CAS  Article  Google Scholar 

  31. Public Health Laboratory Service/Communicable Disease Surveillance Centre. Outbreak of hospital acquired multidrug-resistant tuberculosis. Commun Dis Rep Wkly 1995; 5: 161

    Google Scholar 

  32. Moro ML, Gori A, Errante I, et al. An outbreak of multidrug-resistant tuberculosis involving HIV-infected patients of two hospitals in Milan, Italy. AIDS 1998; 12: 1095–102

    PubMed  CAS  Article  Google Scholar 

  33. Ritacco V, Di Lonardo M, Reniero A, et al. Nosocomial spread of human immunodeficiency-related multidrug-resistant tuberculosis in Buenos Aires. J Infect Dis 1997; 176: 637–42

    PubMed  CAS  Article  Google Scholar 

  34. Coninx R, Pfyffer GE, Mathieu C, et al. Drug resistant tuberculosis in prisons in Azerbaijan: case study. BMJ 1988; 316: 1423–5

    Article  Google Scholar 

  35. Gilbert GL. Multidrug-resistant tuberculosis: prevention is better than cure. Med J Aust 1996; 164: 121–4

    PubMed  CAS  Google Scholar 

  36. Kochi A, Vareldzis B, Styblo K. Multidrug-resistant tuberculosis and its control. Res Microbiol 1994; 144: 104–10

    Article  Google Scholar 

  37. McDermottW, Muschenheim C, Hadley SJ, et al. Streptomycin in the treatment of tuberculosis in humans. Ann Intern Med 1947; 27: 769–822

    Google Scholar 

  38. David HL. Probability distribution of drug-resistant mutants in unselected populations of Mycobacterium. tuberculosis. Appl Microbiol 1970; 20: 810–14

    PubMed  CAS  Google Scholar 

  39. Mitchison DA. How drug resistance emerges as a result of poor compliance during short course chemotherapy for tuberculosis. Int J Tuberc Lung Dis 1998; 2: 10–5

    PubMed  CAS  Google Scholar 

  40. Iseman MD, Sbarbaro JA. Short course chemotherapy of tuberculosis. Am Rev Respir Dis 1991; 143: 697–8

    PubMed  CAS  Google Scholar 

  41. Hong Kong Chest Service/British Medical Research Council. Controlled trials of 2, 4, and 6 months of pyrazinamide in 6-month, three-times-weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin, and pyrazinamide: results at 30 months. Am Rev Respir Dis 1991; 143: 700–6

    Google Scholar 

  42. Combs DL, O’Brien PJ, Geiter LJ. USPHS tuberculosis short-course chemotherapy trial 21: effectiveness, toxicity, and acceptability: the report of final results. Ann Intern Med 1990; 112: 397–406

    PubMed  CAS  Google Scholar 

  43. Centers for Disease Control. Initial therapy for tuberculosis in the era of multidrug resistance: recommendations of the Advisory Council for the Elimination of Tuberculosis. MMWR Morb Mortal Wkly Rep 1993; 42(RR-7): 1–8

    Google Scholar 

  44. American Thoracic Society/Centers for Disease Control. Treatment of tuberculosis and tuberculosis infection in adults and children. Am J Respir Crit Care Med 1994; 149: 1359–74

    Google Scholar 

  45. Global Tuberculosis Programme. Treatment of tuberculosis: guidelines for national programmes. 2nd ed. Geneva: World Health Organization, 1997. Publication no. WHO/TB/97.220

    Google Scholar 

  46. Chaulk CP, Moore Rice K, Rizzo R, et al. Eleven years of community-based directly observed therapy for tuberculosis. JAMA 1995; 274: 945–51

    PubMed  CAS  Article  Google Scholar 

  47. Mitchison DA. The origins of DOT. Int J Tuberc Lung Dis 1998; 2: 863–5

    PubMed  CAS  Google Scholar 

  48. Weis SE, Slocum PC, Biais FX, et al. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N Engl J Med 1994; 330: 1179–84

    PubMed  CAS  Article  Google Scholar 

  49. Chaulk CP, Kazandjian VA. Directly observed therapy for treatment completion of pulmonary tuberculosis: consensus statement of the Public Health Tuberculosis Guidelines Panel. JAMA 1998; 279: 943–8

    PubMed  CAS  Article  Google Scholar 

  50. Wardman AG, Knox AJ, Muers MF, et al. Profiles of non-compliance with antituberculous therapy. Br J Dis Chest 1988; 82: 285–9

    PubMed  CAS  Article  Google Scholar 

  51. Bayer R, Stayton C, Desvarieux M, et al. Directly observed therapy and treatment completion for tuberculosis in the United States: is universal supervised therapy necessary? Am J Public Health 1998; 88: 1052–8

    PubMed  CAS  Article  Google Scholar 

  52. Tuberculosis programme: framework for effective tuberculosis control. Geneva: World Health Organization, 1994. Publication no. WHO/TB/94.179

  53. Murray CJL, DeLonghe E, Chum HJ, et al. Cost effectiveness of chemotherapy for pulmonary tuberculosis in three sub-Saharan African countries. Lancet 1991; 338: 1305–8

    PubMed  CAS  Article  Google Scholar 

  54. Results of directly observed short-course chemotherapy in 112 842 Chinese patients with smear-positive tuberculosis. Chinese Tuberculosis Control Collaboration. Lancet 1996; 347: 358–62

    Google Scholar 

  55. Raviglione MC, Dye C, Schmidt S, et al. Assessment of worldwide tuberculosis control. Lancet 1997; 350: 624–9

    PubMed  CAS  Article  Google Scholar 

  56. Chaulet P. Compliance with chemotherapy for tuberculosis: responsibilities of the Health Ministry and of physicians. Bull Int Union Tuberc Lung Dis 1990–1991; 66 Suppl.: 33–5

    PubMed  Google Scholar 

  57. Byrd RB, Horn BR, Solomon DA, et al. Treatment of tuberculosis by the nonpulmonary physician. Ann Intern Med 1977; 86: 799–802

    PubMed  CAS  Google Scholar 

  58. Bloch AB, Simone PM, McCray E, et al. Preventing multidrug-resistant tuberculosis. JAMA 1996; 275: 487–9

    PubMed  CAS  Article  Google Scholar 

  59. Wenger PN, Otten J, Breeden A, et al. Control of nosocomial transmission of multidrug-resistant Mycobacterium tuberculosis among healthcare workers and HIV-infected patients. Lancet 1995; 345: 235–40

    PubMed  CAS  Article  Google Scholar 

  60. Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care facilities, 1994. MMWR Morb Mortal Wkly Rep 1994; 43 (RR-13): 1–132

  61. Bates JH, Nardell E. Institutional control measures for tuberculosis in the era of multiple drug resistance: ACCP/ATS consensus conference. Chest 1995; 108: 1690–710

    Article  Google Scholar 

  62. Barnes PF. The influence of epidemiologic factors on drug resistance rates in tuberculosis. Am Rev Respir Dis 1987; 136: 325–8

    PubMed  CAS  Article  Google Scholar 

  63. Ben-Dov I, Mason GR. Drug-resistant tuberculosis in southern Californian hospitals: trends from 1969 to 1984. Am Rev Respir Dis 1987; 135: 1307–10

    PubMed  CAS  Google Scholar 

  64. Riley LW, Arathoon E, Loverde VD. The epidemiologic patterns of drug-resistant Mycobacterium tuberculosis infections. Am Rev Respir Dis 1989; 139: 1282–5

    PubMed  CAS  Google Scholar 

  65. Telzak EE, Sepkowitz K, Alpert P, et al. Multidrug-resistant tuberculosis in patients without HIV infection. N Engl J Med 1995; 333: 907–11

    PubMed  CAS  Article  Google Scholar 

  66. Salomon N, Permian DC, Friedmann P, et al. Predictors and outcome of multidrug-resistant tuberculosis. Clin Infect Dis 1995; 21: 1245–52

    PubMed  CAS  Article  Google Scholar 

  67. Daley CL, Small PM, Schecter GF, et al. An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus: an analysis using restriction-fragment-length polymorphisms. N Engl J Med 1992; 326: 231–5

    PubMed  CAS  Article  Google Scholar 

  68. Centers for Disease Control and Prevention. Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: principles of therapy and revised recommendations. MMWR Morb Mortal Wkly Rep 1998; 47(RR-20): 1–58

    Google Scholar 

  69. Park MM, Davis AL, Schluger NW, et al. Outcome of MDR-TB patients, 1983–1993: prolonged survival with appropriate therapy. Am J Respir Crit Care Med 1996; 153: 317–24

    PubMed  CAS  Google Scholar 

  70. Mannheimer SB, Sepkowitz KA, Stoeckle M, et al. Risk factors and outcome of human immunodeficiency virus-infected patients with sporadic multi drug-resistant tuberculosis in New York City. Int J Tuberc Lung Dis 1997; 1: 319–25

    PubMed  CAS  Google Scholar 

  71. Kim TC, Blackman RS, Heatwole KM, et al. Acid-fast bacilli in sputum smears of patients with pulmonary tuberculosis. Prevalence and significance of negative smears pretreatment and positive smears post-treatment. Am Rev Respir Dis 1984; 129: 264–8

    PubMed  CAS  Google Scholar 

  72. Tenover FC, Crawford JT, Huebner RE, et al. The resurgence of tuberculosis: is your laboratory ready? J Clin Microbiol 1993; 31: 767–70

    PubMed  CAS  Google Scholar 

  73. Huebner RE, Good RC, Tokars JI. Current practices in mycobacteriology: results of a survey of state public health laboratories. J Clin Microbiol 1993; 31: 771–5

    PubMed  CAS  Google Scholar 

  74. Inderlied CB, Salfinger M. Antimicrobial agents and susceptibilty tests: mycobacteria. In: Murray PR, Baron EJ, Pfaller MA, et al, editors. Manual of clinical microbiology. 6th ed. Washington, D.C.: American Society for Microbiology, 1995: 1385–404

    Google Scholar 

  75. Anargyros P, Astill DSJ, Lim ISL. Comparison of improved B ACTEC and Lowenstein-Jensen media for culture of mycobacteria from clinical specimens. J Clin Microbiol 1990; 28: 1288–91

    PubMed  CAS  Google Scholar 

  76. Garza-Gonzalez E, Guerrero-Olazaran M, Tijerina-Mechaca, et al. Determination of drug susceptibility of Mycobacterium tuberculosis through mycolic acid analysis. J Clin Microbiol 1997; 35: 1287–9

    PubMed  CAS  Google Scholar 

  77. Heifets L, Cangelosi GA. Drug susceptibility testing of Mycobacterium tuberculosis — a neglected problem at the turn of the century. Int J Tuberc Lung Dis 1999; 3: 564–81

    PubMed  CAS  Google Scholar 

  78. Rieder HL. Sputum smear conversion during directly observed treatment for tuberculosis. Tuber Lung Dis 1996; 77: 124–9

    PubMed  CAS  Article  Google Scholar 

  79. Kritski AL, Rodrigues de Jesus LS, Andrade MK, et al. Retreatment tuberculosis cases: factors associated with drug resistance and adverse outcomes. Chest 1997; 111: 1162–7

    PubMed  CAS  Article  Google Scholar 

  80. Crofton J. The prevention and management of drug-resistant tuberculosis. Bull Int Union Tuberc Lung Dis 1987; 62: 6–11

    PubMed  CAS  Google Scholar 

  81. Harkin TJ, Harris HW. Treatment of multidrug-resistant tuberculosis. In: Rom WN, Gray SM, editors. Tuberculosis. New York: Little, Brown & Company (Inc.), 1996: 843–50

    Google Scholar 

  82. Davidson PT, Le HQ. Drug treatment of tuberculosis — 1992. Drugs 1992; 43: 651–73

    PubMed  CAS  Article  Google Scholar 

  83. McClatchy JK, Kanes W, Davidson PT, et al. Cross-resistance in M. tuberculosis to kanamycin, capreomycin and viomycin. Tubercle 1977; 58: 29–34

    PubMed  CAS  Article  Google Scholar 

  84. Peloquin CA. Pharmacology of the antimycobacterial drugs. Med Clin North Am 1993; 77: 1253–62

    PubMed  CAS  Google Scholar 

  85. Aranda CP. Second-line agents: p-aminosalicylic acid, ethionamide, cycloserine, and thiacetazone. In: Rom WN, Gray SM, editors. Tuberculosis. New York: Little,Brown & Company (Inc.), 1996:811–6

    Google Scholar 

  86. Ji B, Lounis N, Masio C, et al. In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis. Antimicrob Agents Chemother 1998; 42: 2066–9

    PubMed  CAS  Google Scholar 

  87. Saito H, Sato K, Tomioka H, et al. In vitro antimycobacterial activity of a new quinolone, levofloxacin (DR-3355). Tuber Lung Dis 1995; 76: 377–80

    PubMed  CAS  Article  Google Scholar 

  88. Garcia-Rodriguez JA, Gomez Garcia AC. In vitro activities of quinolones against mycobacteria. J Antimicrob Chemother 1993; 32: 797–808

    PubMed  CAS  Article  Google Scholar 

  89. Alangaden GJ, Lerner SA. The clinical use of the fluoro-quinolones for the treatment of mycobacterial diseases. Clin Infect Dis 1997; 25: 1213–21

    PubMed  CAS  Article  Google Scholar 

  90. Kennedy N, Berger L, Curram J, et al. Randomized controlled trial of a drug regimen that includes ciprofloxacin for the treatment of pulmonary tuberculosis. Clin Infect Dis 1996; 22: 827–33

    PubMed  CAS  Article  Google Scholar 

  91. Sirgel FA, Botha FJ, Parkin DP, et al. The early bactericidal activity of ciprofloxacin in patients with pulmonary tuberculosis. Am J Respir Crit Care Med 1997; 156: 901–5

    PubMed  CAS  Google Scholar 

  92. Tsukamura M, Nakamura E, Yoshi S, et al. Therapeutic effect of a new antibacterial substance ofloxacin (DL8280) on pulmonary tuberculosis. Am Rev Respir Dis 1985; 131: 352–6

    PubMed  CAS  Google Scholar 

  93. Yew WW, Kwan SY, Ma WK, et al. In vitro activity of ofloxacin against Mycobacterium tuberculosis and its clinical efficacy in multiply resistant pulmonary tuberculosis. J Antimicrob Chemother 1990; 26: 227–36

    PubMed  CAS  Article  Google Scholar 

  94. Hong Kong Chest Service/British Medical Research Council. A controlled study of rifabutin and an uncontrolled study of ofloxacin in the retreatment of patients with pulmonary tuberculosis resistant to isoniazid, streptomycin and rifampicin. Tuber Lung Dis 1992; 73: 59–67

    Article  Google Scholar 

  95. Sullivan EA, Kreiswirth BN, Palumbo L, et al. Emergence of fluoroquinolone-resistant tuberculosis in New York City. Lancet 1995; 345: 1148–50

    PubMed  CAS  Article  Google Scholar 

  96. Xu C, Kreiswirth BN, Sreevatsan S, et al. Fluoroquinolone resistance associated with specific gyrase mutations in clinical isolates of multidrug-resistant Mycobacterium tuberculosis. J Infect Dis 1996; 174: 1127–30

    PubMed  CAS  Article  Google Scholar 

  97. Kaplan JA, Krieff DM. Quinolones for the treatment and prophylaxis of tuberculosis. Ann Pharmacother 1996; 30: 1020–2

    PubMed  CAS  Google Scholar 

  98. Berning SE, Madsen L, Iseman MD, et al. Long-term safety of ofloxacin and ciprofloxacin in the treatment of mycobacterial infections. Am J Respir Crit Care Med 1995; 151: 2006–9

    PubMed  CAS  Google Scholar 

  99. Berning SE, Huitt GA, Iseman MD, et al. Malabsorption of antituberculosis medications by a patient with AIDS. N Engl J Med 1992; 327: 1817–8

    PubMed  CAS  Article  Google Scholar 

  100. Iseman MD, Madsen L, Goble M, et al. Surgical intervention in the treatment of pulmonary disease caused by drug-resistant Mycobacterium tuberculosis. Am Rev Respir Dis 1990; 141: 623–5

    PubMed  CAS  Article  Google Scholar 

  101. Muthuswamy P, Chechani V, Barker W. Surgical management of pulmonary tuberculosis [abstract]. Am Rev Respir Dis 1992; 145: A816

    Google Scholar 

  102. Pomerantz M, Brown JM. Surgery in the treatment of multi-drug-resistant tuberculosis. Clin Chest Med 1997; 18: 123–30

    PubMed  CAS  Article  Google Scholar 

  103. Mitchison DA, Nunn AJ. Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis. Am Rev Respir Dis 1986; 133: 423–30

    PubMed  CAS  Google Scholar 

  104. Frieden TR, Sherman LF, Maw KL, et al. A multi-institutional outbreak of highly drug-resistant tuberculosis: epidemiology and clinical outcomes. JAMA 1996; 276: 1229–35

    PubMed  CAS  Article  Google Scholar 

  105. Carpels G, Fissette K, Limbana V, et al. Drug resistant tuberculosis in sub Saharan Africa: an estimation of incidence and cost for the year 2000. Tuber Lung Dis 1995; 76: 480–6

    PubMed  CAS  Article  Google Scholar 

  106. Blumberg UM, Watkins DL, Berschling JD, et al. Preventing the nosocomial transmission of tuberculosis. Ann Intern Med 1995; 122: 658–63

    PubMed  CAS  Google Scholar 

  107. Maloney SA, Pearson ML, Gordon MT, et al. Efficacy of control measures in preventing nosocomial transmission of multi-drug-resistant tuberculosis to patients and health care workers. Ann Intern Med 1995; 122: 90–5

    PubMed  CAS  Google Scholar 

  108. Adal KA, Anglim AM, Palumbo CL, et al. The use of high-efficiency particulate air-filter respirators to protect hospital workers from tuberculosis: a costeffectiveness analysis. N Engl J Med 1994; 331: 169–73

    PubMed  CAS  Article  Google Scholar 

  109. Centers for Disease Control. The use of preventative therapy for tuberculous infection in the United States: recommendations of the Advisory Committee for Elimination of Tuberculosis. MMWR Morb Mortal Wkly Rep 1990; 39(RR-8): 9–12

    Google Scholar 

  110. International Union Against Tuberculosis Committee on Prophylaxis. Efficacy of various durations of isoniazid preventative therapy for tuberculosis: 5 years of follow-up in the IUAT trial. Bull World Health Organ 1982; 60: 555–64

    Google Scholar 

  111. Snider DE, Caras GJ, Koplan JP. Preventative therapy with isoniazid: cost-effectiveness of different durations of therapy. JAMA 1986; 255: 1579–83

    PubMed  Article  Google Scholar 

  112. O’Brien RJ, Perriens JH. Preventative therapy for tuberculosis in HIV infection: the promise and the reality. AIDS 1995; 9: 665–73

    PubMed  Article  Google Scholar 

  113. World Health Organization/International Union Against Tuberculosis and Lung Disease. Tuberculosis preventative therapy in HIV-infected individuals: a joint statement of the WHO Tuberculosis Programme and the Global Programme on AIDS, and the International Union Against Tuberculosis and Lung Disease (IUATLD). Wkly Epidemiol Rec 1993; 68: 361–8

    Google Scholar 

  114. Koplan JP, Farer LS. Choice of preventative treatment for isoniazid-resistant tuberculous infection. JAMA 1980; 244: 2736–40

    PubMed  CAS  Article  Google Scholar 

  115. Villarino ME, Ridzon R, Weismuller PC, et al. Rifampin preventive therapy for tuberculosis infection: experience with 157 adolescents. Am J Respir Crit Care Med 1997; 155: 1735–8

    PubMed  CAS  Google Scholar 

  116. Polesky A, Farber HW, Gottlieb DJ, et al. Rifampin preventive therapy for tuberculosis in Boston’s homeless. Am J Respir Crit Care Med 1996; 154: 1473–7

    PubMed  CAS  Google Scholar 

  117. Centers for Disease Control. Management of persons exposed to multidrug-resistant tuberculosis. MMWR Morb Mortal Wkly Rep 1992; 41(RR-11): 61–71

    Google Scholar 

  118. Passannante MR, Gallagher CT, Reichman LB. Preventative therapy for contacts of multidrug-resistant tuberculosis: a Delphi survey. Chest 1994; 106: 431–4

    PubMed  CAS  Article  Google Scholar 

  119. Stevens JP, Daniel TM. Chemoprophylaxis of multidrug-resistant tuberculous infection in HIV-uninfected individuals using ciprofloxacin and pyrazinamide: a decision analysis. Chest 1995; 108: 712–7

    PubMed  CAS  Article  Google Scholar 

  120. Horn DL, Hewlett D, Alfalla C, et al. Limited tolerance of ofloxacin and pyrazinamide prophylaxis against tuberculosis. N Engl J Med 1994; 330: 1241

    PubMed  CAS  Article  Google Scholar 

  121. Villarino ME, Simone PM, McCray E, et al. Preventive therapy for multidrug-resistant tuberculosis. JAMA 1996; 276: 28

    Article  Google Scholar 

  122. Brewer TF, Colditz GA. Bacille Calmette-Guerin vaccination for the prevention of tuberculosis in health care workers. Clin Infect Dis 1995; 20: 136–42

    PubMed  CAS  Article  Google Scholar 

  123. Stevens JP, Daniel TM. Bacille Calmette-Guerin immunization of healthcare workers exposed to multidrug-resistant tuberculosis: a decision analysis. Tuber Lung Dis 1996; 77: 315–21

    PubMed  CAS  Article  Google Scholar 

  124. Jenney AWJ, Spelman DW. In support of Bacillus of Calmette and Guerin for healthcare workers. Infect Control Hosp Epidemiol 1998; 19: 191–3

    PubMed  CAS  Article  Google Scholar 

  125. Colditz GA, Brewer TF, Berkey CS, et al. Efficacy of BCG vaccine in the prevention of tuberculosis: meta-analysis of the published literature. JAMA 1994; 271: 698–702

    PubMed  CAS  Article  Google Scholar 

  126. Centers for Disease Control. The role of BCG vaccine in the prevention and control of tuberculosis in the United States. MMWR Morb Mortal Wkly Rep 1996; 45(RR-4): 1–18

    Google Scholar 

  127. O’Brien RJ, Vernon AA. New tuberculosis drug development. How can we do better? Am Rev Respir Crit Care Med 1998; 157: 1705–7

    Google Scholar 

  128. Moulding TS. Should isoniazid be used in retreatment of tuberculosis despite acquired isoniazid resistance. Am Rev Respir Dis 1981; 123: 262–4

    PubMed  CAS  Google Scholar 

  129. Victor TC, Warren R, Butt JL, et al. Genome and MIC stability in Mycobacterium tuberculosis and indications for continuation of use of isoniazid in multidrug-resistant tuberculosis. J Med Microbiol 1997; 46: 847–57

    PubMed  CAS  Article  Google Scholar 

  130. Klemens SP, DeStefano MS, Cynamon MH. Therapy of multidrug-resistant tuberculosis: lessons from studies with mice. Antimicrob Agents Chemother 1993; 37: 2344–7

    PubMed  CAS  Article  Google Scholar 

  131. De Cian W, Sassella D, Wynne BA. Clinical experience with rifabutin in the treatment of mycobacterial infections. Scand J Infect Dis 1995; Suppl. 98: 22–6

    Google Scholar 

  132. Heifets LB, Lindholm-Levy PJ, Iseman MD. Rifabutine: minimal inhibitory and bactericidal concentrations for Mycobacterium tuberculosis. Am Rev Respir Dis 1988; 137: 719–21

    PubMed  CAS  Google Scholar 

  133. Gonzalez-Montaner LJ, Natal S, Yongchaiyud P, et al. Rifabutin for the treatment of newly-diagnosed pulmonary tuberculosis: a multinational, randomized, comparative study versus rifampicin. Tuber Lung Dis 1994; 75: 341–7

    PubMed  CAS  Article  Google Scholar 

  134. McGregor MM, Olliaro P, Wolmarans L, et al. Efficacy and safety of rifabutin in the treatment of patients with newly diagnosed pulmonary tuberculosis. Am J Respir Crit Care Med 1996; 154: 1462–7

    PubMed  CAS  Google Scholar 

  135. Grassi C, Peona V. Use of rifabutin in the treatment of pulmonary tuberculosis. Clin Infect Dis 1996; 22 Suppl. 1: S50–4

    PubMed  CAS  Article  Google Scholar 

  136. Hardy DJ, Guay DRP, Jones RN. Clarithromycin, a unique macrolide: a pharmacokinetic, microbiological, and clinical overview. Diagn Microbiol Infect Dis 1992; 15: 39–53

    PubMed  CAS  Article  Google Scholar 

  137. Hoffner SE, Gezelius L, Olsson-Liljequist B. In vitro activity of fluorinated quinolones and macrolides against drug-resistant Mycobacterium tuberculosis. J Antimicrob Chemother 1997; 40: 885–8

    PubMed  CAS  Article  Google Scholar 

  138. Luna-Herrera J, Reddy VM, Daneluzzi D, et al. Antituberculosis activity of clarithromycin. Antimicrob Agents Chemother 1995; 39: 2692–5

    PubMed  CAS  Article  Google Scholar 

  139. Truffot-Pernot C, Lounis N, Grosset JH, et al. Clarithromycin is inactive against Mycobacterium tuberculosis. Antimicrob Agents Chemother 1995; 39: 2827–8

    PubMed  CAS  Article  Google Scholar 

  140. Cavalieri SJ, Biehle JR, Sanders WE. Synergistic activities of clarithromycin and antituberculous drugs against multidrug-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 1995; 39: 1542–5

    PubMed  CAS  Article  Google Scholar 

  141. Jagannath C, Reddy VM, Kailasam S, et al. Chemotherapeutic activity of clofazimine and its analogues against Mycobacterium tuberculosis: in vitro, intracellular, and in vivo studies. Am J Respir Crit Care Med 1995; 151: 1083–6

    PubMed  CAS  Google Scholar 

  142. Reddy VM, Nadadhur G, Daneluzzi D, et al. Antituberculosis activities of clofazimine and its new analogs B4154 and B4157. Antimicrob Agents Chemother 1996; 40: 633–6

    PubMed  CAS  Google Scholar 

  143. Shah A, Bhagat R, Panchal N. Resistant tuberculosis: successful treatment with amikacin, ofloxacin, clofazimine and PAS. Tuber Lung Dis 1993; 74: 64–7

    PubMed  CAS  Article  Google Scholar 

  144. Chambers HF, Moreau D, Yajko D, et al. Can penicillins and other beta-lactam antibiotics be used to treat tuberculosis? Antimicrob Agents Chemother 1995; 39: 2620–4

    PubMed  CAS  Article  Google Scholar 

  145. Voladri RKR, Lakey DL, Hennigan SH, et al. Recombinant expression and characterization of the major β-lactamase of Mycobacterium tuberculosis. Antimicrob Agents Chemother 1998; 42: 1375–81

    PubMed  CAS  Google Scholar 

  146. Cynamon MH, Palmer GS. In vitro activity of amoxicillin in combination with clavulanic acid against Mycobacterium tuberculosis. Antimicrob Agents Chemother 1983; 24: 429–31

    PubMed  CAS  Article  Google Scholar 

  147. Nadler JP, Berger J, Nord JA, et al. Amoxicillin-clavulanic acid for treating drug-resistant Mycobacterium tuberculosis. Chest 1991; 99: 1025–6

    PubMed  CAS  Article  Google Scholar 

  148. Yew WW, Wong CF, Lee J, et al. Do β-lactam-β-lactamase inhibitor combinations have a place in the treatment of multi-drug-resistant pulmonary tuberculosis. Tuber Lung Dis 1995; 76: 90–2

    PubMed  CAS  Article  Google Scholar 

  149. Chambers HF, Kocagoz T, Sipit T, et al. Activity of amoxicillin/clavulanate in patients with tuberculosis. Clin Infect Dis 1998; 26: 874–7

    PubMed  CAS  Article  Google Scholar 

  150. Wayne LG. Dormancy of Mycobacterium tuberculosis and latency of disease. Eur J Clin Microbiol Infect Dis 1994; 13: 908–14

    PubMed  CAS  Article  Google Scholar 

  151. Wayne LG, Sramek HA. Metronidazole is bactericidal to dormant cells of Mycobacterium tuberculosis. Antimicrob Agents Chemother 1994; 38: 2054–8

    PubMed  CAS  Article  Google Scholar 

  152. Dhillon J, Alien BW, Hu Y-M, et al. Metronidazole has no antibacterial effect in Cornell model murine tuberculosis. Int J Tuberc Lung Dis 1998; 2: 736–42

    PubMed  CAS  Google Scholar 

  153. Oleksijew A, Meulbroek J, Ewing P, et al. In vivo efficacy of ABT-255 against drug-sensitive and drug-resistant Mycobacterium tuberculosis strains. Antimicrob Agents Chemother 1998; 42: 2674–7

    PubMed  CAS  Google Scholar 

  154. Grandoni JA, Marta PT, Schloss JV. Inhibitors of branched-chain amino acid biosynthesis as potential antituberculosis agents. J Antimicrob Chemother 1998; 42: 475–82

    PubMed  CAS  Article  Google Scholar 

  155. Amaral L, Kristiansen JE, Abebe LS, et al. Inhibition of the respiration of multidrug-resistant clinical isolates of Mycobacterium tuberculosis by thioridazine: potential use for initial therapy of freshly diagnosed tuberculosis. J Antimicrob Chemother 1996; 38: 1049–53

    PubMed  CAS  Article  Google Scholar 

  156. Condos R, Rom WN, Schluger NW. Treatment of multidrug-resistant pulmonary tuberculosis with interferon-gamma via aerosol. Lancet 1997; 349: 1513–5

    PubMed  CAS  Article  Google Scholar 

  157. Prior JG, Khan AA, Cartwright KAV, et al. Immunotherapy with Mycobacterium vaccae combined with second line chemotherapy in drug-resistant abdominal tuberculosis. J Infection 1995; 31: 59–61

    CAS  Article  Google Scholar 

  158. Rom WN, Yie T-A, Tchou-Wong K-M. Development of a suicide gene as a novel approach to killing Mycobacterium tuberculosis. Am J Respir Crit Care Med 1997; 156: 1993–8

    PubMed  CAS  Google Scholar 

  159. Farmer P, Kim JY. Community based approaches to the control of multidrug-resistant tuberculosis: introducing “DOTS-plus”. BMJ 1998; 317: 671–4

    PubMed  CAS  Article  Google Scholar 

  160. Fujiwara PI, Larkin C, Frieden TR. Directly observed therapy in New York City: history, implementation, results and challenges. Clin Chest Med 1997; 18: 135–48

    PubMed  CAS  Article  Google Scholar 

  161. Kim SJ, Hong YP. Drug resistance of Mycobacterium tuberculosis in Korea. Tuber Lung Dis 1992; 73: 219–24

    PubMed  CAS  Article  Google Scholar 

  162. Kim SJ, Bai GH, Hong YP. Drug-resistant tuberculosis in Korea, 1994. Int J Tuberc Lung Dis 1997; 1: 302–8

    PubMed  CAS  Google Scholar 

  163. Boulahbal F, Khaled S, Tazir M. The interest of follow-up of resistance of the tubercle bacillus in the evaluation of a programme. Bull Int Union Tuberc Lung Dis 1989; 64(3): 23–5

    PubMed  CAS  Google Scholar 

  164. Styblo K, Dankova D, Drapela J, et al. Epidemiological and clinical study of tuberculosis in the district of Kolin, Czechoslovakia: report for the first 4 years of the study (1961–64). Bull World Health Organ 1967; 37: 819–74

    PubMed  CAS  Google Scholar 

Download references

Author information

Affiliations

  1. Institute of Tropical Medicine, Nationalestraat 155, B-2000, Antwerpen, Belgium

    Ivan Bastian & Robert Colebunders

Authors
  1. Ivan Bastian
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert Colebunders
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ivan Bastian.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Bastian, I., Colebunders, R. Treatment and Prevention of Multidrug-Resistant Tuberculosis. Drugs 58, 633–661 (1999). https://doi.org/10.2165/00003495-199958040-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199958040-00005

Keywords

  • Tuberculosis
  • Adis International Limited
  • Isoniazid
  • Rifabutin
  • Cycloserine